Menu
Recruiting NCT05838183

Interstitial Lung Disease and Obstructive Sleep Apnea

Observational ILD OSA

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: The relationship between imaging and ROSE and NGS.
Who it may be relevant to
Registry conditions: ILD OSA. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Study on the Clinical Characteristics of Interstitial Lung Disease and Obstructive Sleep Apnea

Overview

Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively

Interventions

  • Diagnostic test The relationship between imaging and ROSE and NGS
    The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed

Primary outcome measures

  • imaging changes and ROSE and NGS in patients [Time frame: 2Day]
Secondary outcome measures (1)
  • Severity and biological examination of OSA patients [Time frame: 2Day]

Eligibility criteria

Inclusion criteria

  • over 18 years old and under 80 years old.
  • Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome.
  • Patient is conscious and capable of signing informed consent.
  • The patient may wear a polysomnograph.

Exclusion criteria

  • malignant tumors.
  • severe heart failure.
  • uremia.
  • autoimmune diseases.
  • pulmonary embolism, and end-stage chronic obstructive pulmonary disease.
  • Patients with mental illnesscannot sign informed consent on their own.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Tianjin Medical University General Hospital — Tianjin

Identifiers

NCT: NCT05838183 · Dliu

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗